newsroom.csl.com – MashupMD

Mashup Score: 1

CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human]) - 9 month(s) ago

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human])…

Source: newsroom.csl.com

Categories: General Medicine News, Cardiologists

Tweet Tweets with this article
- lipiddoc
  
  https://t.co/1bFskr9gY9

Mashup Score: 1

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - 9 month(s) ago

Study conducted by Meiji Seika Pharma in Japan Short communication follows previously published data in The Lancet Infectious Diseases demonstrating Immunological Non-Inferiority to Wuhan Strain…

Source: newsroom.csl.com

Categories: General Medicine News, Infectious Disease

Tweet Tweets with this article
- AmeshAA
  
  “New data demonstrates continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of duration of immune response” https://t.co/rGJAjSntL0